Truist on Insmed (INSM): 'TPIP Data Is a Clearing Event'
Tweet Send to a Friend
Truist Securities analyst Nicole Germino reiterated a Buy rating and $108.00 price target on Insmed (NASDAQ: INSM).The analyst commented: "Investor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
